Evidence map›Paper›PMID 34988444›Full record

ArticleJAC-antimicrobial resistance2022

Sub-growth-inhibitory concentrations of omadacycline inhibit

Alisa W Serio, S Ken Tanaka, Kelly Wright, Lynne Garrity-Ryan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Omadacycline is activeAntimicrobial agents and chemotherapy · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Alisa W SerioParatek Pharmaceuticals, Inc., 1000 First Ave, Suite 200, King of Prussia, PA 19406, USA.ORCID https://orcid.org/0000-0002-5625-0792
S Ken TanakaParatek Pharmaceuticals, Inc., 1000 First Ave, Suite 200, King of Prussia, PA 19406, USA.
Kelly WrightParatek Pharmaceuticals, Inc., 1000 First Ave, Suite 200, King of Prussia, PA 19406, USA.
Lynne Garrity-RyanParatek Pharmaceuticals, Inc., 1000 First Ave, Suite 200, King of Prussia, PA 19406, USA.
Paratek Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the effect of sub-growth-inhibitory concentrations of omadacycline on

methodsFollowing determination of the MICs of omadacycline and comparator antibiotics, the strain was grown in the presence of individual antibiotics and the percentage of haemolysis assayed; 'washout' experiments were performed with omadacycline only.

resultsOmadacycline inhibited

conclusionsOmadacycline's

Identifiers

PMID34988444
PMCPMC8693163
OpenAlexW4200350528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.